Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Operations (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Cash from Operations for 3 consecutive years, with 33824000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 11.7% to 33824000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 143392000.0, a 30.9% increase, with the full-year FY2024 number at 194409000.0, down 0.57% from a year prior.
  • Cash from Operations was 33824000.0 for Q3 2025 at Inhibrx Biosciences, down from 29953000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 29953000.0 in Q2 2025 to a low of 63050000.0 in Q1 2024.
  • A 3-year average of 45016333.33 and a median of 43720000.0 in 2024 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 47.78% in 2025; the steepest drop was 11.7% in 2025.
  • Inhibrx Biosciences' Cash from Operations stood at 56821000.0 in 2023, then rose by 23.06% to 43720000.0 in 2024, then rose by 22.63% to 33824000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Cash from Operations are 33824000.0 (Q3 2025), 29953000.0 (Q2 2025), and 35895000.0 (Q1 2025).